recent publications
-
academic article
- Good, C. W., Steinhubl, S. R., Brennan, D. M., Lincoff, A. M., Topol, E. J., Berger, P. B. Is there a clinically significant interaction between calcium channel antagonists and clopidogrel? Results from the clopidogrel for the reduction of events during observation (credo) trial Circulation-Cardiovascular Interventions 2012 5:77-81 DOI:10.1161/circinterventions.111.963405 PMID:22319066
- Weber, M., Bhatt, D. L., Brennan, D. M., Hankey, G. J., Steinhubl, S. R., Johnston, S. C., Montalescot, G., Mak, K. H., Fox, K. A. A., Easton, D. J., Topol, E. J., Hamm, C. W., et al. High-sensitivity c-reactive protein and clopidogrel treatment in patients at high risk of cardiovascular events: A substudy from the charisma trial Heart 2011 97:626-631 DOI:10.1136/hrt.2010.210419 PMID:21393433
- Hankey, G. J., Hacke, W., Easton, J. D., Johnston, S. C., Mas, J. L., Brennan, D. M., Bhatt, D. L., Fox, K. A. A., Topol, E. J., Investigators, Charisma Trial Effect of clopidogrel on the rate and functional severity of stroke among high vascular risk patients a prespecified substudy of the clopidogrel for high atherothrombotic risk and ischemic stabilization, management and avoidance (charisma) trial Stroke 2010 41:1679-1683 DOI:10.1161/strokeaha.110.586727 PMID:20595658
- Berger, P. B., Bhatt, D. L., Fuster, V., Steg, P. G., Fox, K. A. A., Shao, M. Y., Brennan, D. M., Hacke, W., Montalescot, G., Steinhubl, S. R., Topol, E. J., Investigators, Charisma Bleeding complications with dual antiplatelet therapy among patients with stable vascular disease or risk factors for vascular disease Circulation 2010 121:2575-2583 DOI:10.1161/circulationaha.109.895342 PMID:20516378
- Dosh, K., Berger, P. B., Marso, S., van Lente, F., Brennan, D. M., Charnigo, R., Topol, E. J., Steinhubl, S. Relationship between baseline inflammatory markers, antiplatelet therapy, and adverse cardiac events after percutaneous coronary intervention an analysis from the clopidogrel for the reduction of events during observation trial Circulation-Cardiovascular Interventions 2009 2:503-512 DOI:10.1161/circinterventions.109.879312 PMID:20031767
- Steinhubl, S. R., Bhatt, D. L., Brennan, D. M., Montalescot, G., Hankey, G. J., Eikelboom, J. W., Berger, P. B., Topol, E. J., Investigators, Charisma Aspirin to prevent cardiovascular disease: The association of aspirin dose and clopidogrel with thrombosis and bleeding Annals of Internal Medicine 2009 150:379-386 DOI:10.7326/0003-4819-150-6-200903170-00006 PMID:19293071
- Aronow, H. D., Steinhubl, S. R., Brennan, D. M., Berger, P. B., Topol, E. J., Investigators, Credo Bleeding risk associated with 1 year of dual antiplatelet therapy after percutaneous coronary intervention: Insights from the clopidogrel for the reduction of events during observation (credo) trial American Heart Journal 2009 157:369-374 DOI:10.1016/j.ahj.2008.09.011 PMID:19185647
- Best, P. J. M., Steinhubl, S. R., Berger, P. B., Dasgupta, A., Brennan, D. M., Szczech, L. A., Califf, R. M., Topol, E. J., Investigators, Credo The efficacy and safety of short- and long-term dual antiplatelet therapy in patients with mild or moderate chronic kidney disease: Results from the clopidogrel for the reduction of events during observation (credo) trial American Heart Journal 2008 155:687-693 DOI:10.1016/j.ahj.2007.10.046 PMID:18371477
- Bhattacharyya, T., Nicholls, S. J., Topol, E. J., Zhang, R. L., Yang, X., Schmitt, D., Fu, X. M., Shao, M. Y., Brennan, D. M., Ellis, S. G., Brennan, M. L., Allayee, H., et al. Relationship of paraoxonase 1 (PON1) gene polymorphisms and functional activity with systemic oxidative stress and cardiovascular risk JAMA-Journal of the American Medical Association 2008 299:1265-1276 DOI:10.1001/jama.299.11.1265 PMID:18349088 PMCID:PMC3014051
- Wang, T. H., Bhatt, D. L., Fox, K. A. A., Steinhubl, S. R., Brennan, D. M., Hacke, W., Mak, K. H., Pearson, T. A., Boden, W. E., Steg, P. G., Flather, M. D., Montalescot, G., et al. An analysis of mortality rates with dual-antiplatelet therapy in the primary prevention population of the charisma trial European Heart Journal 2007 28:2200-2207 DOI:10.1093/eurheartj/ehm274 PMID:17673448
- Saw, J., Brennan, D. M., Steinhubl, S. R., Bhatt, D. L., Mak, K. H., Fox, K., Topol, E. J., Investigators, Charisma Lack of evidence of a clopidogrel-statin interaction in the charisma trial Journal of the American College of Cardiology 2007 50:291-295 DOI:10.1016/j.jacc.2007.01.097 PMID:17659194
- Shishehbor, M. H., Zhang, R. L., Medina, H., Brennan, M. L., Brennan, D. M., Ellis, S. G., Topol, E. J., Hazen, S. L. Systemic elevations of free radical oxidation products of arachidonic acid are associated with angiographic evidence of coronary artery disease Free Radical Biology and Medicine 2006 41:1678-1683 DOI:10.1016/j.freeradbiomed.2006.09.001 PMID:17145556 PMCID:PMC1945055
- Bhatt, D. L., Fox, K. A. A., Hacke, W., Berger, P. B., Black, H. R., Boden, W. E., Cacoub, P., Cohen, E. A., Creager, M. A., Easton, J. D., Flather, M. D., Haffner, S. M., et al. Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events New England Journal of Medicine 2006 354:1706-1717 DOI:10.1056/NEJMoa060989 PMID:16531616
- Mukherjee, D., Topol, E. J., Moliterno, D. J., Brennan, D. M., Ziada, K., Cho, L., Steinhubl, S. R., Investigators, Credo Extracardiac vascular disease and effectiveness of sustained clopidogrel treatment Heart 2006 92:49-51 DOI:10.1136/hrt.2005.064501 PMID:15845611 PMCID:PMC1860989
- Gurm, H. S., Lincoff, A. M., Kleiman, N. S., Kereiakes, D. J., Tcheng, J. E., Aronow, H. D., Askari, A. T., Brennan, D. M., Topol, E. J. Double jeopardy of renal insufficiency and anemia in patients undergoing percutaneous coronary interventions American Journal of Cardiology 2004 94:30-34 DOI:10.1016/j.amjcard.2004.03.025 PMID:15219504
- Merlini, P. A., Rossi, M., Menozzi, A., Buratti, S., Brennan, D. M., Moliterno, D. J., Topol, E. J., Ardissino, D. Thrombocytopenia caused by abciximab or tirofiban and its association with clinical outcome in patients undergoing coronary stenting Circulation 2004 109:2203-2206 DOI:10.1161/01.cir.0000127867.41621.85 PMID:15117843
- Aronow, H. D., Novaro, G. M., Lauer, M. S., Brennan, D. M., Lincoff, A. M., Topol, E. J., Kereiakes, D. J., Nissen, S. E. In-hospital initiation of lipid-lowering therapy after coronary intervention as a predictor of long-term utilization - a propensity analysis Archives of Internal Medicine 2003 163:2576-2582 DOI:10.1001/archinte.163.21.2576 PMID:14638557
- Roffi, M., Mukherjee, D., Chew, D. P., Bhatt, D. L., Cho, L., Robbins, M. A., Ziada, K. M., Brennan, D. M., Ellis, S. G., Topol, E. J. Lack of benefit from intravenous platelet glycoprotein iib/iiia receptor inhibition as adjunctive treatment for percutaneous interventions of aortocoronary bypass grafts - a pooled analysis of five randomized clinical trials Circulation 2002 106:3063-3067 DOI:10.1161/01.cir.0000041250.89627.a9 PMID:12473552
- Gurm, H. S., Brennan, D. M., Booth, J., Tcheng, J. E., Lincoff, A. M., Topol, E. J. Impact of body mass index on outcome after percutaneous coronary intervention (the obesity paradox) American Journal of Cardiology 2002 90:42-5 DOI:10.1016/s0002-9149(02)02384-6 PMID:12088778